Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.

Abstract

BACKGROUND:

The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors.

PATIENTS AND METHODS:

One hundred and sixteen patients with metastatic neuroendocrine tumors were included. All patients were pre-therapeutically staged with morphological imaging procedures and with somatostatin receptor scintigraphy. The scintigraphy was positive in all cases. The patients were treated with 162-200 mCi/m2 body surface. In 57 patients, the quality of life was assessed with the National Cancer Institute grading criteria (NCI-CTC). Restaging was performed 8-12 weeks after the last treatment cycle. Blood samples were drawn every 2 weeks after the treatment to evaluate toxicity.

RESULTS:

Complete remissions were found in 4%, partial remissions in 23%, stabilization in 62% and progressive disease in 11%. A significant reduction of symptoms was found in 83%. No serious adverse event occurred and the toxicity was acceptable.

CONCLUSION:

90Y-DOTATOC is a safe and effective treatment for patients with metastatic neuroendocrine tumors.

• Authors: Flavio Forrer, Christian Waldherr, Helmut R Maecke, Jan Mueller-Brand
• Journal: Anticancer research (Anticancer Res) 2006 Jan-Feb Vol. 26 Issue 1B Pg. 703-7 ISSN: 0250-7005 [Print] Greece
• PMID: 16739341 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Radiopharmaceuticals
• Yttrium Radioisotopes
• 90Y-octreotide, DOTA-Tyr(3)-
• Octreotide

Topics

• Humans
• Intestinal Neoplasms (radiotherapy)
• Lung Neoplasms (radiotherapy)
• Middle Aged
• Neoplasms, Unknown Primary (radiotherapy)
• Neuroendocrine Tumors (radiotherapy)
• Octreotide (adverse effects, analogs & derivatives, therapeutic use)
• Palliative Care
• Pancreatic Neoplasms (radiotherapy)
• Prospective Studies
• Radiopharmaceuticals (adverse effects, therapeutic use)
• Yttrium Radioisotopes (adverse effects, therapeutic use)